Man­u­fac­tur­ing roundup: AGC Bi­o­log­ics to man­u­fac­ture di­a­betes ther­a­py; Cam­brex caps ac­qui­si­tion of Snap­drag­on Chem­istry

The Wash­ing­ton-based CD­MO AGC Bi­o­log­ics has been tapped to man­u­fac­ture the type 1 di­a­betes treat­ment Tzield from Proven­tion Bio.

AGC Bi­o­log­ics will pro­duce Tzield at its Seat­tle pro­tein bi­o­log­ics site. It was cho­sen af­ter AGC helped to guide the prod­uct through process per­for­mance qual­i­fi­ca­tion (PPQ) man­u­fac­tur­ing and val­i­da­tion batch­es, and, ul­ti­mate­ly, FDA ap­proval. Tzield is the on­ly im­munomod­u­la­to­ry treat­ment ap­proved to de­lay the on­set of Stage 3, type 1 di­a­betes in chil­dren and adults aged eight and old­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER